Fasching, Peter A.

Pembrolizumab for Early Triple-Negative Breast Cancer

Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine

Breast Cancer Treatment StudiesCancer Immunotherapy and Biomarkers

Cited by 3,270

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

von Minckwitz, G., Untch, M., Blohmer, J.-U., Costa, S. D., Eidtmann, H., Fasching, P. A., Gerber, B., Eiermann, W., Hilfrich, J., Huober, J., et al. (2012) · Journal of Clinical Oncology

Breast Cancer Treatment StudiesBreast Lesions and Carcinomas

Cited by 2,659

Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy

Denkert, C., von Minckwitz, G., Darb-Esfahani, S., Lederer, B., Heppner, B. I., Weber, K. E., Budczies, J., Huober, J., Klauschen, F., Furlanetto, J., et al. (2018) · The Lancet Oncology

Breast Cancer Treatment StudiesBreast Lesions and Carcinomas

Cited by 2,157

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

Schmid, P., Cortes, J., Dent, R., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., et al. (2022) · New England Journal of Medicine

Breast Cancer Treatment StudiesCancer Immunotherapy and Biomarkers

Cited by 1,274

Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3

Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martín, M., et al. (2018) · Journal of Clinical Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 1,121

Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies

Pearce, C. L., Templeman, C., Rossing, M. A., Lee, A., Near, A. M., Webb, P. M., Nagle, C. M., Doherty, J. A., Cushing-Haugen, K. L., Wicklund, K. G., et al. (2012) · The Lancet Oncology

Endometriosis Research and TreatmentOvarian cancer diagnosis and treatment

Cited by 939

Overall survival with ribociclib plus fulvestrant in advanced breast cancer

Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martín, M., et al. (2020) · New England Journal of Medicine

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 865

Associations of breast cancer risk factors with tumor subtypes: A pooled analysis from the breast cancer association consortium studies

Yang, X. R., Chang-Claude, J., Goode, E. L., Couch, F. J., Nevanlinna, H., Milne, R. L., Gaudet, M., Schmidt, M. K., Broeks, A., Cox, A., et al. (2011) · JNCI: Journal of the National Cancer Institute

Cancer Risks and FactorsBreast Cancer Treatment Studies

Cited by 691

Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients

Rack, B., Schindlbeck, C., Jückstock, J., Andergassen, U., Hepp, P., Zwingers, T., Friedl, T. W. P., Lorenz, R., Tesch, H., Fasching, P. A., et al. (2014) · JNCI: Journal of the National Cancer Institute

Breast Cancer Treatment StudiesCancer Cells and Metastasis

Cited by 615

Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche

Study, A. O. C., Perry, J. R. B., The GENICA Network, kConFab, Study, T. L. C., The InterAct Consortium, Early Growth Genetics (EGG) Consortium, Day, F., Elks, C. E., Sulem, P., et al. (2014) · Nature

Hypothalamic control of reproductive hormonesGenetic Associations and Epidemiology

Cited by 604

Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk

Study, T. L. C., Day, F. R., The InterAct Consortium, kConFab/AOCS Investigators, Endometrial Cancer Association Consortium, Ovarian Cancer Association Consortium, PRACTICAL consortium, Thompson, D. J., Helgason, H., Chasman, D. I., et al. (2017) · Nature Genetics

Hypothalamic control of reproductive hormonesGenetic Associations and Epidemiology

Cited by 587

Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair

The PRACTICAL Consortium, Day, F. R., kConFab Investigators, AOCS Investigators, Scotland, G., EPIC-InterAct Consortium, Study, L. C., Ruth, K. S., Thompson, D. J., Lunetta, K. L., et al. (2015) · Nature Genetics

Genetic Associations and EpidemiologyBRCA gene mutations in cancer

Cited by 402

Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival

Slamon, D. J., Neven, P., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S., Petrakova, K., Valeria Bianchi, G., Martín, M., Nusch, A., et al. (2021) · Annals of Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 281

Identification of six new susceptibility loci for invasive epithelial ovarian cancer

EMBRACE, Kuchenbaecker, K. B., Collaborators, G. S., Breast Cancer Family Registry, HEBON, KConFab Investigators, Australian Cancer Study (Ovarian Cancer Investigators), Australian Ovarian Cancer Study Group, the Consortium of Investigators of Modifiers of BRCA1 and BRCA2, Ramus, S. J., et al. (2015) · Nature Genetics

BRCA gene mutations in cancerOvarian cancer diagnosis and treatment

Cited by 250

Age- and Tumor Subtype–Specific Breast Cancer Risk Estimates for CH EK 2 *1100delC Carriers

Schmidt, M. K., Hogervorst, F., van Hien, R., Cornelissen, S., Broeks, A., Adank, M. A., Meijers, H., Waisfisz, Q., Hollestelle, A., Schutte, M., et al. (2016) · Journal of Clinical Oncology

BRCA gene mutations in cancerBreast Lesions and Carcinomas

Cited by 173

Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170

EMBRACE, Dunning, A. M., Collaborators, G. S., HEBON, kConFab Investigators, Michailidou, K., Kuchenbaecker, K. B., Thompson, D., French, J. D., Beesley, J., et al. (2016) · Nature Genetics

Genetic Associations and EpidemiologyEstrogen and related hormone effects

Cited by 161

Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant.

Neven, P., Fasching, P. A., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Martín, M., Nusch, A., et al. (2023) · Breast Cancer Research

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 83

Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer

Gass, P., Lux, M. P., Rauh, C., Hein, A., Bani, M. R., Fiessler, C., Hartmann, A., Häberle, L., Pretscher, J., Erber, R., et al. (2018) · BMC Cancer

Breast Cancer Treatment StudiesBreast Lesions and Carcinomas

Cited by 83

Body mass index and breast cancer survival: a Mendelian randomization analysis

Guo, Q., Burgess, S., Turman, C., Bolla, M. K., Wang, Q., Lush, M., Abraham, J., Aittomäki, K., Andrulis, I. L., Apicella, C., et al. (2017) · International Journal of Epidemiology

Cancer Risks and FactorsGenetic Associations and Epidemiology

Cited by 64

Reliability of an e-PRO Tool of EORTC QLQ-C30 for Measurement of Health-Related Quality of Life in Patients With Breast Cancer: Prospective Randomized Trial

Wallwiener, M., Matthies, L., Simoes, E., Keilmann, L., Hartkopf, A. D., Sokolov, A. N., Walter, C. B., Sickenberger, N., Wallwiener, S., Feisst, M., et al. (2017) · Journal of Medical Internet Research

Cancer survivorship and careHealth Systems, Economic Evaluations, Quality of Life

Cited by 55

Predicting attention deficit hyperactivity disorder using pregnancy and birth characteristics

Schwenke, E., Fasching, P. A., Faschingbauer, F., Pretscher, J., Kehl, S., Peretz, R., Keller, A., Häberle, L., Eichler, A., Irlbauer-Müller, V., et al. (2018) · Archives of Gynecology and Obstetrics

Attention Deficit Hyperactivity DisorderPrenatal Substance Exposure Effects

Cited by 39

Multicenter evaluation of blood-based biomarkers for the detection of endometriosis and adenomyosis: a prospective non-interventional study

Burghaus, S., Drazic, P., Wölfler, M., Mechsner, S., Zeppernick, M., Meinhold‐Heerlein, I., Mueller, M. D., Rothmund, R., Vigano, P., Becker, C. M., et al. (2024) · International Journal of Gynecology & Obstetrics

Endometriosis Research and TreatmentEctopic Pregnancy Diagnosis and Management

Cited by 38

A comprehensive evaluation of interaction between genetic variants and use of menopausal hormone therapy on mammographic density

Rudolph, A., Fasching, P. A., Behrens, S., Eilber, U., Bolla, M. K., Wang, Q., Thompson, D., Czene, K., Brand, J. S., Li, J., et al. (2015) · Breast Cancer Research

Digital Radiography and Breast ImagingGenetic Associations and Epidemiology

Cited by 24

Evaluating the Effectiveness of Mobile Health in Breast Cancer Care: A Systematic Review

Flaucher, M., Zakreuskaya, A., Nissen, M., Mocker, A., Fasching, P. A., Beckmann, M. W., Eskofier, B. M., & Leutheuser, H. (2023) · The Oncologist

Mobile Health and mHealth ApplicationsCancer survivorship and care

Cited by 15